Introduction
Hematopoiesis is a continuous developmental process in which hematopoietic stem cells (HSC) and their progeny make sequential cell fate decisions, producing mature blood cells of the various lineages. The constant generation of appropriate numbers and types of mature cells, as well as the maintenance of HSC, requires a complex regulatory network of exogenous and endogenous signalling which are incompletely understood. 1 In invertebrate and vertebrate developmental systems, molecules belonging to the highly conserved Notch family are known to modulate cell fate. [2] [3] [4] Accumulated evidence indicates that Notch signalling modulates the ability of nonterminally differentiated cells to respond to differentiation and proliferation signals in order to progress to the next developmental stage. Notch receptors are transmembrane glycoproteins that bind to ligands expressed on adjoining cells. They represent a single-pass transmembrane protein composed of a large extracellular domain containing between 29 and 36 epidermal growth factor (EGF)-like repeats in tandem and three cystein-rich Notch/LIN-12 repeats and an intracellular domain consisting of six tandem cdc10/ankyrin repeats, a glutamine-rich domain (OPA), and a PEST sequence critical to downstream signalling. 5 The Notch receptor interacts with a family of transmembrane proteins that serve as ligands, containing EGF repeats and a highly conserved Delta-Serrate-Lag-2 (DSL) domain in the extracellular region. Activation of Notch signalling is mediated through interactions between the DSL domain and specific EGF repeats located in the extracellular portion of the Notch receptor. In the prevailing model of Notch activation, once the ligand is bound, signal transduction takes place, resulting in the appearance of transcription factors such as Hes-1, capable to suppress the transcription of lineage-specific genes. The cell becomes refractory to differentiation signals, an effect transient and reversible; once Notch activation ceases the cell is able to differentiate.
If a role for Notch-1 has been clearly demonstrated in promoting T-cell development while inhibiting B-cell differentiation, 6 a role for Notch receptors and their ligands in the regulation of HSC has recently emerged. Four different Notch genes have been identified in mice and humans, two of which, Notch-1 and Notch-2, are known to be expressed in the hematopoietic system, in primitive and mature cells within the different cell compartment 7, 8 as well as in adult medullar stroma cells. Two Notch ligand families, Delta and Serrate/Jagged ligands, have been identified in mammals, including Delta-1, 3 for the Delta family and Jagged-1, 2 for the Serrate/Jagged family. Human Delta-1 as well as human Jagged-1 are expressed in human CD34 þ cells and in adult bone marrow stroma cells. 7, 8 Similarly, Jagged-2 is expressed on murine Lin À c-kit þ cells. 9 A number of recent studies have provided evidence that ligand-induced Notch signalling favored HSC self-renewal, [10] [11] [12] [13] increased the numbers of progenitors, 7, 8, [14] [15] [16] [17] and promoted HSC survival. 18 A new member of the Delta family has been cloned by us and others, from either endothelial cell or placenta libraries, named Delta-4. [19] [20] [21] Like other Delta ligands, Delta-4 possesses an extracellular region containing several EGF-like domains and a DSL domain required for receptor binding. Human Delta-4 was found to be highly expressed within the vascular endothelium, 20 but its expression was also found in a wide range of adult and fetal tissues, including sites of hematopoiesis. 8 We investigated if Delta-4 was able to influence in vitro the fate of human cord blood CD34
þ CD38 low cells stimulated by early acting cytokines. Since Notch ligands were considered to exert their effects through membrane-bound expression from stroma cells, we ascertained the effects of Delta-4 on HSC by using a coculture between HSC and S17 cells engineered to express Delta-4 as membrane-bound protein (mbDelta4). Our results reveal that the major activity of mbDelta-4 consists in reducing HSC proliferation, thus leading to the maintenance of the LTC-IC potential.
Methods

Construction, and production of retroviruses
Retroviral vectors coding for full-length 19 human Delta-4 cDNA were derived from the MPSVpac vector carrying the puromycin N-acetyl transferase (pac) gene driven by an internal murine phosphoglycerase kinase (pgk) promoter and a murine embryonic stem cell virus (MESV) LTR. 22 The unmodified vector served as control. Full-length Delta-4 cDNA (2058 kb) (mbDelta-4) was PCR-amplified to introduce unique 5 0 -XhoI and 3 0 -EcoRI restriction sites and a Kozak sequence (ACCGCC) in the original cDNA (Advantage-HF kit, Clontech Lab. Inc, Palo Alto CA, USA). The PCR products were ligated into the MSCVpac retroviral vector, sequenced, and one clone was selected for base perfect match with the original cDNA.
Viral supernatants were generated using 293-EBNA cells (Invitrogen, Carlsbad, CA, USA) by transfecting the Delta-4 constructs using the Exgen 500 reagent (Euromedex, France) as previously described. 23 
Generation of Delta-4-Fc protein
This construct was engineered to encode the extracellular domain of human Delta-4 fused in frame to a sequence of human IgG1-Fc fragment. The human Delta-4 cDNA was PCRamplified using a sense primer (5 0 -CGTACTCGAGATGGCGG-CAGCGTCCCGGAGC-3 0 ) and an antisense primer (5 0 -CTGAG-GATCCCAGGGGAAGCTGGGCGGCAAGCCCAC-3 0 ). The product of amplification was digested by Xho1 and BamH1, and cloned into the Xho1 and BamH1 sites of phT75SS-hIgG1Fc expression vector. The resulting construct was introduced into HEK293 cells using the Exgen 500 reagent to generate a stable cell population for protein production. The presence of soluble Delta-4Fc in the conditioned medium of G418-resistant cells (InVitrogen) was revealed by slot-dot using Protein A horseradish peroxidase linked (Amersham). Conditioned medium was first 10-fold concentrated into dialysis tubing by contact with a layer of polyethylene glycol compound (Sigma), and dialyzed against 2 M NaCl 50 mM borate pH 8.5. The dialyzed protein concentrate was pumped over a Protein A column (HiTrap Protein A, Amersham), and the column was extensively washed with 2 M NaCl 50 mM borate pH 8.5. Bound protein was eluted with 100 mM glycine, pH 3, and neutralized with 2 M Tris pH 11. Purity assessed by separating proteins using 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and silver staining (SilverQuest kit, InVitrogen) was always superior to 80%.
Generation of S17 and NIH3T3 stromal cell populations S17 cells 24 were grown in minimal essential medium (a-MEM) supplemented with 10% fetal calf serum (FCS, InVitrogen, France). They were infected with 0.1 ml of the viral supernatants (containing the control vector, or the mbDelta-4-expressing vector) in the presence of 4 mM polybrene (Sigma, France). Two days after infection, puromycin selection (4 mg/ml, Sigma, France) was performed to generate stably transduced cell populations. Each of the two S17 populations (C/S17, or mbD4/S17) was the result of a mixture of at least 10 different clones. NIH3T3 cells were transfected with the same procedure.
Polyclonal antibodies against a peptide in the extracellular domain of mouse Delta-4 (TPGDDLRPETSPGNS) were raised in rabbits and subsequently peptide affinity purified (Research Genetics, Huntsville, AL, USA). C/S17 and mbD4/S17 cells were labelled according to standard procedures using a biotinylated anti-rabbit antibody (Immunotech, Marseille, France) and streptavidin conjugated to R-Phycoerythrin (Caltag, Burlingame, CA, USA). Fluorescence analysis was performed on a FACScan (Becton Dickinson, San Diego, CA, USA).
Separation of CD34
þ CD38 low cells
Cord blood samples were obtained with informed consent according to approved institutional guidelines, and were subjected to standard CD34 immunomagnetic bead separation (Miltenyi Biotech, Auburn, CA, USA). Sorting of the CD34 þ CD38 low fraction was performed using a FACSVantage (Becton-Dickinson) as previously described. 25 In some experiments, CD34
þ CD38 low cells were labelled with the carboxy fluorescein diacetate succinimidy enterdye (CFSE) to track the successive cell division during culture, as previously described. 26 
Cell culture
Cultures were initiated by plating 5000 CD34 þ CD38 low cells in 24-well plates precoated with C/S17 or mbD4/S17 in a-MEM containing 10% FCS (Stem Cell Technology, Vancouver, Canada). The following cytokines were added : PEG-rhu-MGDF (50 ng/ml; Kirin, Brewery, Japan), rhu-IL3 (100 U/ml, Novartis), rhu-Flt-3 ligand (100 ng/ml, Immunex), and rhu-SCF (50 ng/ml, Amgen). At day 7, to avoid any deleterious effect of 7-day aged stroma, the cultures were disrupted by vigorous pipeting and scraping. Nucleated cells were counted, and 5000 output nucleated cells were replated into a new 24-well plate precoated with C/S17 and mbD4/S17 stroma lines. This procedure was repeated for two consecutive weeks. At days 7, 14, 21, and 28, output CD34 þ cells were sorted to assess their functional potential.
Some cultures were initiated at single CD34 þ CD38 low cell level in the same conditions. At day 10, the resulting clones were examined, and their size was evaluated (10-100 cells; 101-1000 cells; 41000 cells).
In another series of experiments, CFSE-labelled CD34 þ CD38 low cells were cultured on the different S17 stroma lines as described above. Cells having divided once during 48 h were selected, and plated onto fresh stromas. Two days later, cells having performed four more divisions (a total of five from the onset of the culture) were sorted again, and their LTC-IC potentials were analyzed. All cultures were kept at 371C in an air atmosphere supplemented with 5% CO 2 and saturated with humidity.
The activity of the Delta4-Fc protein was assessed by precoating for 1 h at 371C wells of nontissue culture-treated plates with a solution of 10 mg/ml of goat F(ab 0 )2 anti-human IgG1 Fc specific (Caltag, Tebu), and of 25 ng/ml Retronectin (Takara, Biowhittaker, UK) in 1 Â PBS. Wells were washed with 1 Â PBS, blocked with 1 Â PBS containing 10% FCS, incubated with a solution of Delta4-Fc (10 mg/ml) in 1 Â PBS for 2 h at 371C, and washed extensively with 1 Â PBS. Irrelevant human IgG1 (10 mg/ml) serves as negative control. Culture experiments of CD34 þ CD38 low cells with Delta4-Fc were performed in the same conditions as above, with the exception of the culture medium (STEMSPAN SFEM medium, Stem Cell Technologies, Vancouver, Canada þ cytokines).
Assessment for cell apoptosis and cell cycle by propidium iodide analysis Seven days after the onset of the culture, nucleated cells were resuspended at a concentration of 5 Â 10 6 cells per ml in 0.15 mol/l NaCl, 0.1 mol/l Tris-HCl pH 7.6, then diluted with 20 vol of 0.1% (wt/vol) Na citrate, pH 7.6, 10 mmol/l NaCl, 50 mg/ ml RNase A, 0.1% NP40, and 10 mg/ml propidium iodide. The cells were then incubated at 41C for 24 h before flow cytometric analysis (Becton Dickinson, FACSsort, France). At least 10 000 cells per sample were analyzed for cell cycle progression.
Apoptosis was analyzed as follows. Purified CD34 þ cells were pelleted, and cells were washed once with 1 Â PBS, and once in Annexin V binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 ). Cells were transferred to a tube, and 1 ml of Annexin V-FITC and 2.5 ml dissolved propidium iodide were added per tube and allowed to incubate on ice for 15 min in the dark. Cells were analyzed for fluorescence on a FACScan using the CellQuest software.
Phenotype of output CD34
þ cells
The phenotype of output CD34 þ cells was assessed by flow cytometry after labelling with the following mAbs: CD7-PE (Becton Dickinson), CD38-PE (Becton Dickinson) CD90-FITC (Immunotech), CD45RA (Pharmingen) and CD10PE (Becton Dickinson). Analysis was performed on a FACScant using CellQuest software.
Functional assays
Quantification of CFC in CD34
þ cells was performed using standard methylcellulose colony assay using previously described criteria. 27 LTC-IC potential was performed as previously described. 27 The LTC-IC frequency was established by culturing them in limiting dilution. The absolute number of LTC-IC was then derived from the calculate frequency. 27 Myeloid (G/M) and/or lymphoid (B, NK) potential of CD34 þ cells was assessed in a permissive culture as previously described. 28 Wells with significant cell proliferation were selected, cells were collected and counted, and their phenotype assessed by flow cytometry after labelling with the following mAbs: CD19-PE (Becton Dickinson), CD15-FITC (Dako Corp.), and CD56-PE-Cy5 (Immunotech).
Transplantation of output CD34 þ cells into NOD-SCID mice was performed using mice bred and maintained at the Gustave Roussy Institute. NOD/SCID mice at 8-10 weeks of age were girradiated at 250 cGy the day of transplantation, and human cells were injected via the retro-orbital sinus. When fresh CD34 þ CD38 low cells were transplanted, 10 5 irradiated (20 Gy) CD34
neg cord blood cells were coinjected as carrier cells. At 10 weeks, mice were killed, cells were harvested from both femurs and tibias, and analyzed for engraftment. After blocking with anti-mouse CD16/32 FcgIII/II receptor (Pharmingen, Becton Dickinson) antibody, cells were stained with FITC-conjugated human CD45 (Immunotech).
Real-time RT-PCR studies of Hes-1 expression
Total RNA was extracted from output CD34 þ cells using the SV total RNA isolation kit, and DNAse-treated (Promega) before synthesizing cDNA using the SuperScriptII kit (InVitrogen Life Technologies, Inc.). Primers and probes of Hes-1 were as follows: Hes-1 forward primer, 5 0 TGGAAATGACAGTGAA GCACCT3 0 , Hes-1 reverse primer, 5 0 GTTCATGCACTCGCT GAAGC3 0 , Hes-1 probe 5 0 GCGAGATGACGGCTGCGCTG3 0 . Probes were labelled at the 5 0 end with the reporter dye molecule FAM and at the 3 0 end with the quencher dye molecule TAMRA (Applied Biosystems, Foster City, CA, USA). The b2-microglobulin gene was used as an endogenous control (Applied Biosystems). PCR amplification was carried out for 10 min at 951C followed by 50 cycles of 1 min at 601C and 15 s at 951C in an ABI PRISM 7700 Sequence Detector 5 (Applied Biosystems). Hes-1 RNA expression was normalized using b2-microglobulin as the endogenous standard and JY cells (American Type Culture Collection, Manassas, VA, USA) as a positive standard (normalized target value).
Statistical analysis
Statistical significance was determined by Student's t-test (paired data analysis).
Results
Ectopic expression of Delta-4 in S17 cells and coculture condition
Since Notch ligands have been described to exert their activity as membrane-bound molecule, we first assessed the role of Delta-4 in modulating HSC fate via activation of their Notch receptors using a feeder engineered to express the human membrane-bound Delta-4 (mbDelta-4). The choice of the appropriate feeder was conditioned by the amount of expression of the various Notch ligands evaluated by RT-PCR. S17 and NIH3T3 cells were chosen, since they did not express Delta-4 and were already used to evaluate the role of several Notch ligands on HSC potential. [14] [15] [16] [17] Of note, S17 cells slightly expressed Jagged-1 transcripts but not the others Notch ligands (data not shown).
The effects of mbDelta-4 were first analyzed by using S17 cells. Two cell feeders have been established: one line containing the control vector (C/S17), and the other one expressing the mbDelta-4 protein (mbD4/S17). Expression of mbDelta-4 protein at the surface of mbD4/S17 cells was detected by flow cytometric analysis (Figure 1) , without inducing the expression of the other Notch ligands (data not shown). To evaluate the effects of Delta-4-expressing stromas on the progeny of HSC during 4 weeks of culture, human primitive CD34 þ CD38 low cord blood cells were plated onto the different transfected stromas in the presence of early acting cytokines (rhuIL-3, rhuSCF, rhuPEG-MGDF, and rhuFlt3-L). At day 7, nucleated cells were enumerated, and output CD34
þ cells were sorted to analyze their potential (CFCs, lympho/myeloid differentiative potential, LTC-IC). The study was pursued another week by replating 5000 output nucleated cells onto fresh stromas. The same procedure was repeated at day 14 and 21 for two more weeks, thus, enabling the evaluation from day 7 to 28 of culture, of the impact of Delta-4 on the number of nucleated cells, CD34 þ cells, CFCs, and LTC-ICs.
mbD4/S17 reduces nucleated cell production by modifying the cell cycle status
The fold increase in total cell number obtained during the 4-week coculture on S17 cells is depicted in Figure 2 . During the first week, the fold increase in the total cell number was lower for cells growing on mbD4/S17 cells (16713, mean7s.d.; Po0.05), as compared to cells growing on C/S17 stromas (54724). Despite the wide inter-cord blood variability between the samples, the cumulative nucleated cell production in the population grown on mbD4/S17 was always lower in all four timepoints, as compared to that grown on C/S17. Thus, on day 28, culture of CD34 þ CD38 low cells on mbD4/S17 led to a 12-fold reduced cell production (Po0.05). Nucleated cell production between populations grown on C/S17 and parental S17 was not different (data not shown).
To explore the mechanisms involved in the decrease of nucleated cell production by mbD4/S17, we analyzed the cloning efficiency and the proliferative potential of single CD34 þ CD38 low cells cultured on the S17 stromas. The number and the size of the proliferative clones were evaluated at day 10 ( Figure 3a) . The cloning efficiency, that is, the number of wells containing active cell proliferation (more than 10 cells/well) was identical whatever the stroma (3172% C/S17, 3172% mbD4/ S17), suggesting that mbD4/S17 did not act on input CD34 þ CD38 low cell survival. However, mbD4/S17 gave rise to mainly small-size clones (10-100 cells), while C/S17 gave rise to intermediate-size clones (101-1000 cells). These observations indicated that mbD4/S17 modulated either apoptosis or cell proliferation rate of daughter cells. Involvement of apoptosis in mbD4/S17 activity was excluded since Annexin V staining of output cells after 7 days of culture revealed the similarity in the mean viability of the two populations (Figure 3b ; 1174 for C/S17 and 1574 for mbD4/S17). On the other hand, in agreement with the decreased cell production mediated by mbD4/S17, we observed in Figure 3c a lower percentage of cells in S phase, as compared to the cells grown on C/S17 (1374 vs 2377%; P ¼ 0.003), with a higher proportion of cells in G0/G1 Figure 1 Delta-4 expression in S17 cells. Fluorescent histograms of S17 cells stained with antibodies, an affinity-purified rabbit antiserum raised to the extracellular domain of murine Delta-4. The y-axis represents cell number, and the x-axis represents log fluorescence intensity. The gray histogram represents mbD4/S17 stroma and the white C/S17 stroma. Mean fluorescence intensity : C/S17 ¼ 4.77; mbD4/S17 ¼ 11.90.
Figure 2
Effect of mbD4/S17 on nucleated cell production. 5000 CD34 þ CD38 low cells were added to wells coated with C/S17, or mbD4/S17 stromas in the presence of rhuSCF, rhuIL-3, rhuPEG-MGDF, and rhuFlt-3L. Cells were harvested at the indicated times, and 5000 output nucleated cells were replated onto the two different S17 stromas for another week of culture. This procedure was repeated for two additional weeks (results from five experiments). Significant difference, 
Delta4 reduces HSC proliferation
that mbD4/S17 counteracted cell proliferation induced by cytokines.
mbD4/S17 maintains a high proportion of CD34 bright cells
We next evaluated the influence of mbD4/S17 on the CD34 þ cell production with high mean fluorescence intensity. At day 7, a high percentage of output CD34 bright cells (6875-7477%) was maintained with no difference between the two different cultures (Figure 4a) . Thereafter, in contrast to C/S17, mbD4/S17 was able to maintain a high proportion of CD34 bright cells (6578, day 14; 40710, day 21, 4773, day 28 for mbD4/S17 vs 29716, day 14; 979, day 21, 1172, day 28, for C/S17). However, the total number of CD34 bright cells was similar to both conditions of culture due to reduced expansion of nucleated cells with mbD4/S17 (data not shown). These data indicated that mbD4/S17 reduced cell production with a longterm maintenance of high percentage of CD34 bright cells.
mbD4/S17 enhances BFU-E production
We analyzed whether the ectopic expression of mbDelta-4 in S17 cells would alter the output CFC progenitors from input CD34 þ CD38 low cells. The clonogenicity in semisolid medium of output CD34 þ cells cultured on mbD4/S17 and C/S17, sequentially generated at day 7, 14, and 21, was progressively lowered (data not shown). Examination of the type of colony did not reveal any difference in the number of CFU-GM per 1000 output CD34
þ cells between the different cultures (data not shown). However, a constant and significant 2-3-fold increase in the number of BFU-E among the CD34 þ cells exposed to mbD4/S17 was observed throughout the culture (Figure 4b ), responsible for a slight but not significant increase in total CFC number from CD34 þ cells stimulated by mbD4/S17. mbDelta4 maintains the lymphoid and myeloid potential of output CD34 bright cells
To assess the early commitment of output CD34 þ cells grown on mbD4/S17 and C/S17, we analyzed the expression of antigens such as CD7 and CD45RA representing committed lymphoid progenitors and CD38, Thy-1, and CD10 representing immature progenitors. At 7 days of culture, 60% of CD34 bright cells derived from mbD4/S17 culture coexpressed high levels of the CD7 antigen vs only 24% for CD34 bright cells generated on C/S17 (Figure 5a ). CD45RA as well as the other markers studied did not display any modification of expression in the two CD34 þ populations ( Figure 5 and data not shown). Coexpression of CD7 and CD45RA on CD34 þ cells represents the phenotype for the committed lymphoid precursor, 29 suggesting that activation by mbD4/S17 stroma promotes lymphoid differentiation of input CD34 þ CD38 low cells. To test this hypothesis, fresh CD34 þ CD38 low cells and output CD34 þ cells from the 7-day culture on S17 stromas were seeded at one cell per well on MS-5 cells, maintained for 4 weeks in culture in the presence of six cytokines. The phenotype of each clone was determined (CD15 ¼ G/M; CD19 ¼ B; CD56 ¼ NK) (Figure 5b) . The cloning efficiency, that is, the number of wells containing active cell proliferation (more than 10 cells/well) was identical independent of the stroma (5275% C/S17, 5476% mbD4/S17), slightly lower than the one of fresh CD34 þ CD38 low cells (6477%). Output CD34 þ cells cultured on C/S17 stroma were characterized by a diminished differentiative potential, compared to the one of fresh CD34 þ CD38 low cells, with a decreased proportion of two-/three-lineage clones (3177 for CD34 þ cells cultured on C/S17 vs 74711 for fresh CD34 þ CD38 low cells), and an increased proportion of onelineage clones (6977 for CD34 þ cells cultured on C/S17 stroma vs 26710 for fresh CD34 þ CD38 low cells). Inversely, mbD4/S17 significantly prevented the loss of the differentiative potential of output CD34 þ cells. CD34 þ cells derived from cultures on mbD4/S17 stroma generated higher proportion of two/three-lineage clones (56713, n ¼ 6, Po0.01), and a lower proportion of one-lineage clones (44713 n ¼ 6, Po0.01). These data indicate that mbD4/S17 limited the loss of the differentiative potential in culture. Furthermore, examination of the differentiation potential of CD34 þ CD7 þ cells (putative committed lymphoid progenitors) vs CD34 þ CD7 À cells at the end of Effect of mbD4/S17 on CD34 þ cells and BFU-E. 5000 CD34 þ CD38 low cells were added to wells coated with C/S17, or mbD4/S17 stromas in the presence of rhuSCF, rhuIL-3, rhuPEG-MGDF, and rhuFlt-3L. Cells were harvested at the indicated times, and 5000 output nucleated cells were replated onto the two different S17 stromas for another week of culture. This procedure was repeated for two additional weeks (results from five experiments Figure 6a , the total number of LTC-IC-derived CFC from output CD34 þ cells decreased throughout the 3-week coculture whatever the stroma. The striking observation was the significantly higher production of CFC-derived LTC-IC from CD34 þ cells exposed to mbD4/S17 at day 7, 14 (Po0.01), and day 21 (Po0.05). The total number of LTC-IC-derived CFC produced from 5000 input CD34 þ CD38 low cells was also significantly higher in the presence of mbD4/S17 by day 7 (Po0.05) and day 21 Figure 5 (a) FACS analysis for CD34, CD7, and CD45RA expression. 5000 CD34 þ CD38 low cells were added to wells coated with C/S17 or mbD4/S17 stromas as previously described. Seven days later nucleated cells were sorted and analyzed for CD34, CD7, and CD45RA expression (FACS analysis of one out of three independent experiments). Numbers in the graph are the percentages of gate events within the quadrant. (b) Phenotype of clones derived from input CD34 þ CD38 low cells and output CD34 þ cells grown on C/S17 and mbD4/S17 stroma. 5000 CD34 þ CD38 low cells were added to wells coated with C/S17 or mbD4/S17 stromas as previously described. CD34 þ cells were sorted 7 days later and examined for their myeloid (G/M) and lymphoid potential (B/NK) in a permissive culture. Proportions of the different types of clones were calculated as the ratio of clones containing one, two, or three lineages per total number of clones analyzed (mean of six experiments).
Figure 6
(a) Effect of mbD4/S17 on LTC-IC-derived CFC during the culture. 5000 CD34 þ CD38 low cells were added to wells coated with C/S17 or mbD4/S17 stromas in the presence of rhuSCF, rhuIL-3, rhuPEG-MGDF, and rhuFlt-3L. Cells were harvested at the indicated times and 5000 output nucleated cells were replated onto the two different S17 stromas for another week of culture. This procedure was repeated for an additional week (results from five experiments). At days 7, 14, and 21, output CD34 þ cells were sorted and 1000 output CD34 þ cells from each were then assayed for LTC-IC activity. þ CD38 low cells were cultured with cytokines in the presence of C/S17 (white circle) or mbD4/S17 (gray circle). On day 2, cells from each culture that had completed 1 division were sorted and replated on fresh stromas. On day 4, cells having accomplished five divisions were sorted and assessed for LTC-IC activity. Each point represents the number of CFC produced after 5 weeks on MS-5 cells by 10 CD34
þ CD38 low cells that have accomplished five divisions.
(Po0.02), as compared to C/S17 (Figure 6b þ cells grown on C/S17 were significantly diminished (0.0270.02), Po0.01; n ¼ 5), compared to that in input cells. Interestingly, mbD4/S17 maintained LTC-IC with high proliferative capacity at day 7, since the average number of CFC per LTC-IC was identical to that from input CD34 þ CD38 low (respectively, 23711 vs 2675). In contrast, the average number of CFC per LTC-IC was reduced in LTC-IC produced on C/S17 (1378). On day 7, the absolute number of LTC-IC was significantly higher (Po0.05) in cell population grown on mbD4/S17. From 5000 input CD34 þ CD38 low cells containing initially an average of 915 (7916) LTC-ICs, the mean production was 4765 (72125) LTC-ICs at day 7 on mbD4/S17, compared to 1660 (7990) LTC-IC for C/S17. Thus mbD4/S17 induced a true expansion of LTC-IC.
Since an inverse correlation has been observed between LTC-IC potential and the number of cell division, 25, 26, 30 the maintenance of the LTC-IC potential by mbDelta-4 could be only due to the reduced number of cell divisions. To test this hypothesis, we compared the LTC-IC potential of CD34 þ CD38 low cells having undergone the same number of divisions. CFSE-labelled CD34 þ CD38 low cells were cultured on the different S17 stromas, and at day 2, cells having accomplished one division in each culture were purified, and replated on fresh stromas for two additional days. LTC-IC activity was assessed in subset of cells having undergone five divisions from day 0. The results of three experiments are depicted in Figure 6c . The retention of LTC-IC activity mediated by mbD4/S17 was observed in all experiments: the geometric mean of LTC-IC-derived CFCs per 10 input CD34 þ CD38 low cells was significantly higher in the population grown on mbD4/ S17 (14727 in Exp1; 40762 in Exp2, 27729 in Exp3, P ¼ 0.03 for all experiments), as compared to the control population (275 in Exp1; 9727 in Exp2; 478 in Exp3). Thus, mbDelta-4 still maintained a high LTC-IC potential in cells having performed a similar number of doubling, indicating that LTC-IC retention by mbDelta4 is also mediated by mechanisms independent of the cell cycle.
mbD4/S17 does not enhance the in vivo marrow-repopulating ability in NOD-SCID mice
Since mbD4/S17 maintained the LTC-IC potential of output CD34 þ cells, we next tested the activity of mbDelta4 on the in vivo marrow-repopulating ability in NOD-SCID mice. For this purpose, we transplanted 2500 fresh CD34 þ CD38 low cells along with 10 5 irradiated (20 Gy) CD34 neg cord blood cells, or all the progeny of 2500 or 10 000 CD34 þ CD38 low cells cultured for 10 days onto C/S17 and mbD4/S17, into sublethally irradiated NOD/SCID mice. To cast off the difference of proliferation, we injected all the progeny of CD34 þ CD38 low cells grown on C/S17 and mbD4/S17 stromas whatever the number of cells. As expected, total cell production was higher in the populations grown on C/S17 (585715 and 600780 fold for 2500 or 10 000 CD34 þ CD38 low cells, respectively) than in the populations grown on mbD4/S17 (110712 and 88716 for 2500 and 10 000 CD34 þ CD38 low cells, respectively). Analysis of the presence of human CD45 þ cells in the bone marrow of engrafted NOD-SCID mice 10 weeks later showed a low chimerism in all conditions. We did not observe any significant difference in the percent of positive mice ( Figure 7 ) in both experiments. Moreover, the level of engraftment between populations grown on C/S17 and mbD4/S17, whatever the number of expanded CD34 þ CD38 low cells was not different (0.1770.25 in Exp1; 4.4713 in Exp2 for C/S17 stroma vs 0.1570.26 in Exp1; 0.270.3 in Exp2 for mbD4/S17 stroma). These data indicated that although mbDelta4 was able to enhance the production of progenitors such as LTC-IC, it did not enhance the production of primitive stem cells such as the long-term SCID repopulating cells.
Assessment of mbDelta-4 specificity
We next raised the question of whether the reduction of cell production and the retention of the primitive potential were specific for mbDelta4. To rule out any role of Jagged-1 (since S17 cells also slightly coexpressed the Jagged-1 ligand), we derived NIH3T3 lines expressing mbDelta-4 to assess Delta-4 activity on CD34 þ CD38 low cells in the same protocol as described above (NIH3T3 cells do not express Jagged-1 and neither other Notch ligands). Expression of mbDelta4 was confirmed on mbD4/3T3 cells (data not shown). The results from two experiments revealed that mbD4/3T3, like mbD4/S17, reduced nucleated cell production from input CD34 þ CD38 low
Figure 7
Effect of mbD4/S17 on engraftment of human cells in marrow of NOD/SCID mice. In all, 2500 fresh CD34 þ CD38 low cells along with 10 5 irradiated (20 Gy) CD34 neg cord blood cells, or all the progeny of 2500 or 10 000 CD34 þ CD38 low cells cultured for 10 days onto C/S17 or mbD4/S17, were transplanted into sublethally irradiated NOD/SCID mice. Analysis of the presence of human CD45 þ cells in the bone marrow of engrafted NOD-SCID mice was performed 10 weeks later. The percent of human CD45 þ cells was established from FACS analysis of at least 10 5 events. Each symbol represents the levels of a single chimeric mouse.
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E Lauret et al cells. In contrast to C/3T3, it maintained a high proportion of CD34 bright cells characterized by a high LTC-IC potential (data not shown). To assess the specific role of mbDelta-4 on cell production with regard to other Notch ligands, we have examined the activity of another Notch ligand, mbDelta-1, by culturing CD34 þ CD38 low cells onto a S17 stroma expressing mbDelta-1 using the protocol described above. In our culture conditions, mbDelta-1 did not modify nucleated cell expansion as compared to control stromas (data not shown). Finally, to assess the potential role of the cytokines, we examined the activity of mbD4/S17 on the progeny of CD34 þ CD38 low using other combinations of cytokines (PEG-MGDF/IL3/Flt-3L/SCF/IL-7 or PEG-MGDF/IL3/Flt-3L/ SCF/G-CSF or PEG-MGDF/IL3/Flt-3L/SCF/GM-CSF). Whatever the combinations used, we still observed the reduced cell expansion in cell populations grown onto mbD4/S17 stroma, indicating that the reduced cell production was not relative to the cytokines used. Taken together, all these data strongly suggested the specific involvement of mbDelta-4 in the observed effects.
To evaluate whether the culture of CD34 þ cells on mbDelta4-expressing stromas induces Notch signalling, we assessed the expression of Hes-1, a well-known target gene of Notch signalling, using quantitative RT-PCR in cells generated by the 7-day coculture of CD34 þ CD38 low cells on both NIH3T3 stromas. Indeed, output CD34 þ cells generated in culture with mbD4/3T3 showed a significant increase in Hes-1 mRNA expression, ranging from 1.4-to 28-fold according to the sample, leading to a mean value of 11-fold (n ¼ 5, P ¼ 0.04), as compared to control cells.
Having 12 and cultured CD34 þ CD38 low cells for 7 days. By the end of the culture, we examined the number of nucleated cells, the percent of CD34 þ cells, and their content of CFC and LTC-IC. Like mbDelta4, the presence of immobilized Delta4-Fc and retronectin led to a reduced production of nucleated cell (30717 fold, n ¼ 6, Po0.001), compared to the culture with irrelevant human IgG and retronectin (137758 fold) (Figure 8a ). The same proportion of CD34 þ cells was observed at this time of culture between Delta4-Fc-activated population (33% of CD34 þ cells), and control culture (36% of CD34 þ cells) (Figure 8b ). Furthermore, Delta4-Fc induced a three-fold increase in the number of BFU-E among CD34 þ cells (n ¼ 4, Po0.01). The LTC-IC frequency among these CD34 þ cells was higher in the population stimulated with Delta4-Fc (0.3870.17), compared to the frequency determined in the control population (0.0770.05, n ¼ 6, Po0.01) (Figure 8c) . However, the total number of LTC-IC was similar in both conditions of culture due to reduced expansion of nucleated cells with Delta4-Fc (Figure 8d ). These data indicate that Delta4-Fc shared most of the activities of the membrane-bound protein such as reduced nucleated cell production, enhanced BFU-E production, maintaining of a high LTC-IC potential but does not enhance LTC-IC expansion.
Discussion
We report here a novel activity of a Notch ligand, the ligand Delta4, in which the main activity consists in counteracting cell proliferation of hematopoietic stem cells induced by cytokines. mbDelta4 maintained a high LTC-IC activity in output CD34 þ cells, without retaining a long-term in vivo marrow-repopulating ability in NOD-SCID mice. mbDelta-4 induced the generation of cells of the phenotype of committed lymphoid precursors
, but these cells still retained their capacity to differentiate towards myelopoiesis. All these biological effects were associated with an overexpression of Hes-1, one of the well-known Notch target genes. These results are in agreement with a report indicating that overexpression of mbDelta-4 in murine HSC prevents their reconstitutive ability by blocking their differentiation into preCFU-S and day12CFU-S. 33 The first striking observation was the reduction in the total number of nucleated cells generated in the presence of mbDelta-4, compared to control culture. mbDelta-4 decreases the production of these cells, with neither impact on cell survival nor the recruitment of input CD34 þ CD38 low cells to proliferate, as indicated by the similar frequency of proliferating clones in single cell culture experiments between the different feeders. Instead, mbDelta-4 alters the cell cycle progression of daughter cells, by reducing cell proliferation, as indicated by the higher proportion of cells in G0/G1 phase, and the high proportion of small-size clones. Notch activation in other cellular contexts mediated growth arrest by upregulation of p21
Cip and p27 Kip34 or cell proliferation by upregulation of cyclin D1 and activation of CDK2. 35 Molecular mechanisms specific to the G0/G1 phase involved in the alteration of the cell cycle progression in CD34 þ cells by mbDelta-4 remain to be identified.
The second major result is the enhancement of LTC-IC expansion by mbDelta4, contrary to control cultures. During the first week of culture, mbDelta-4 promotes a five-fold expansion over input LTC-IC, while the LTC-IC quality at day 7 was similar to that of parental CD34 þ CD38 low cells (ie same number of CFC per LTC-IC). These results correlated with the activity of mbDelta4 on the cell cycle and suggest that mbDelta-4 is a regulator of the LTC-IC potential by principally altering their cell cycle progression. However, when we compared the LTC-IC potential in a subset of cells having performed the same number of divisions, mbDelta-4 still maintained a higher LTC-IC potential. This suggests, besides the direct consequence of the reduced number of cell division, the existence of an alternative mechanism unrelated to cell proliferation implicated in the maintenance of LTC-IC potential by mbDelta4. Such maintenance of the LTC-IC potential independent of the mitotic history has been previously demonstrated with the MS-5 cell line, known to express Jagged2 and Delta1 Notch ligands. 25, 26 Although mbDelta4 enhances LTC-IC expansion as compared to control cultures, culture of CD34 þ CD38 low cells on mbD4/ S17 stroma did not enhance the long-term repopulation ability of output CD34 þ cells in NOD-SCID mice. These data are in agreement with previous work showing that contrary to soluble Delta1, soluble Delta4 did not increase the long-term repopulation ability in NOD-SCID mice. 8 Although the NOD/SCID model is not sufficient to observe a two-fold expansion of SRC, which needs recently developed models such as NOD/SCID b2m À/À36 or NOD/SCID gc À/À , 37 we can conclude that mbDelta4 has no major effect on SRC expansion. CD34 þ CD38 low cells stimulated by mbDelta4 mostly generated cells of the seemingly committed lymphoid precursor phenotype (CD34 þ CD45RA þ CD7 þ ). 29 This observation is in agreement with the work of Bernstein's group, 12 which described the generation of such cells after stimulation of CD34 þ CD38 À cells by Delta-1 immobilized on plastic. However, by comparing the lympho/myeloid differentiative potential of single output CD34 þ /CD7 þ vs CD34 þ /CD7À cells generated in culture with mbDelta4 (NK, G/M, B), we did not observe any difference between both populations. mbDelta4 rather maintains a high rate of multipotent clones, thus limiting the loss of the primitive potential. This suggests that in our hands activation of CD34 þ CD38 low cells by mbDelta4 maintains the level of pluripotent precursors, and does not promote the generation of cells exclusively committed towards the lymphoid lineage. Our results question the CD34 þ CD45RA þ CD7 þ phenotype as phenotype of cells possessing only the lymphoid potential. 29 The results with the chimeric Delta4Fc protein, presented as immobilized molecule, indicate that it shares most of the activities of mbDelta4. Delta4Fc reduces cell proliferation, and maintains a higher LTC-IC frequency, as compared to control population. However, Delta4Fc, contrary to mbDelta4, does not increase the total number of LTC-IC, due to the reduced expansion of nucleated cells. This discrepancy suggests that Delta4, presented as membrane-bound molecule, provides additional signals, enabling access of enzymes or other accessory molecules necessary for the complete response. mbDelta4, as Notch ligand, exerts a particular activity by keeping HSC out of the cell cycle, preventing them to lose their primitive potential. These results are in keeping with the general conundrum surrounding the role of Notch receptors in the regulation of HSC. The literature reveals that Notch signalling is able to enhance HSC self-renewal, to enhance HSC proliferation, or to promote cell survival. The role of Notch in HSC selfrenewal has been clearly demonstrated in the case of constitutive activation of the intracellular domain of Notch1 in murine HSC 10, 11 and of activation of the Notch receptors by membrane-bound Jagged1 or Jagged2 or immobilized Delta1. [12] [13] [14] [15] [16] An enhancement of cell proliferation with the retention of the primitive potential has been ascribed to soluble forms of Jagged1 and Delta1. 7, 8, 18 In another study, membrane-bound Jagged2 was enhancing HSC survival. 9 All these studies describing pleiotropic activities of Notch signalling on HSC suggest the existence of different ways of altering the conformation of Notch. Notch signalling occurs through several pathways that may be equally important. Some imply the Notch-CSLHes-bHLH pathways, other pathways are Hes independent. 4 Nevertheless, even if Notch signalling enhances Hes-1 expression, this can lead to opposite activities in the same cellular context, for example, mbDelta-4 inhibits cell proliferation while immobilized Delta1 rather favors HSC self-renewal. 12 The different Notch ligands as well as their different modes of presentation could not act through the same Notch receptor. Alternatively, they could interact with the same receptor but may recruit different intracellular partners depending on signalling intensity, as hypothesized in the signalling threshold model on stem cell fate decision. 38 
